Clinical Trial Update: Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an immune checkpoint inhibitor combined with recombinant human endostatin for leptomeningeal metastasis from lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Lung Cancer

Drugs mentioned

• Endostatin (endostatin)

Snippet

Sponsor: Hebei Medical University | Conditions: Leptomeningeal Metastasis, Immune Checkpoint Inhibitor | Phase 2 | Status: UNKNOWN